Benjamin Ian Bearnot, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Opioid-Related Disorders | 15 | 2023 | 2062 | 2.300 |
Why?
|
Endocarditis | 4 | 2022 | 348 | 1.360 |
Why?
|
Methamphetamine | 1 | 2021 | 152 | 0.710 |
Why?
|
Substance Abuse, Intravenous | 2 | 2022 | 522 | 0.690 |
Why?
|
Needles | 2 | 2020 | 448 | 0.680 |
Why?
|
Refuse Disposal | 1 | 2018 | 31 | 0.660 |
Why?
|
Geographic Information Systems | 2 | 2018 | 281 | 0.660 |
Why?
|
Substance Abuse Treatment Centers | 1 | 2018 | 168 | 0.620 |
Why?
|
Buprenorphine | 5 | 2023 | 640 | 0.610 |
Why?
|
Social Stigma | 2 | 2020 | 698 | 0.560 |
Why?
|
Substance-Related Disorders | 4 | 2021 | 4250 | 0.550 |
Why?
|
Medical Staff, Hospital | 1 | 2019 | 603 | 0.490 |
Why?
|
Central Nervous System Stimulants | 1 | 2021 | 1148 | 0.440 |
Why?
|
Internal Medicine | 1 | 2019 | 1009 | 0.400 |
Why?
|
Health Services Accessibility | 2 | 2019 | 5133 | 0.400 |
Why?
|
Alcoholism | 2 | 2019 | 1904 | 0.400 |
Why?
|
Epidemics | 1 | 2017 | 521 | 0.390 |
Why?
|
Analgesics, Opioid | 6 | 2023 | 3667 | 0.360 |
Why?
|
Endocarditis, Bacterial | 2 | 2022 | 453 | 0.310 |
Why?
|
Self Report | 1 | 2018 | 3548 | 0.300 |
Why?
|
Psychiatry | 1 | 2019 | 1695 | 0.280 |
Why?
|
Hospitals | 1 | 2019 | 3937 | 0.250 |
Why?
|
Mobile Health Units | 2 | 2015 | 80 | 0.240 |
Why?
|
Subacute Care | 2 | 2022 | 168 | 0.200 |
Why?
|
Delivery of Health Care | 1 | 2019 | 5304 | 0.190 |
Why?
|
San Francisco | 1 | 2020 | 159 | 0.190 |
Why?
|
Drug Users | 1 | 2022 | 131 | 0.190 |
Why?
|
Smoking Cessation | 3 | 2022 | 2068 | 0.180 |
Why?
|
Boston | 4 | 2021 | 9305 | 0.180 |
Why?
|
Narcotic Antagonists | 2 | 2023 | 562 | 0.180 |
Why?
|
Harm Reduction | 1 | 2020 | 129 | 0.170 |
Why?
|
Continuity of Patient Care | 2 | 2019 | 1048 | 0.170 |
Why?
|
Hallucinogens | 1 | 2022 | 180 | 0.170 |
Why?
|
Residence Characteristics | 2 | 2019 | 2049 | 0.170 |
Why?
|
Biomedical Research | 1 | 2014 | 3306 | 0.170 |
Why?
|
Marijuana Smoking | 1 | 2022 | 252 | 0.160 |
Why?
|
Emergency Service, Hospital | 1 | 2017 | 7645 | 0.150 |
Why?
|
Alcoholic Beverages | 1 | 2019 | 265 | 0.150 |
Why?
|
Cross-Sectional Studies | 7 | 2022 | 24913 | 0.130 |
Why?
|
Canada | 1 | 2021 | 2061 | 0.130 |
Why?
|
Attitude | 1 | 2020 | 772 | 0.130 |
Why?
|
Cannabis | 1 | 2022 | 432 | 0.130 |
Why?
|
Humans | 30 | 2023 | 742088 | 0.130 |
Why?
|
Health Facilities | 1 | 2019 | 573 | 0.120 |
Why?
|
Commerce | 1 | 2019 | 591 | 0.120 |
Why?
|
Medically Underserved Area | 1 | 2015 | 253 | 0.110 |
Why?
|
Reminder Systems | 1 | 2016 | 370 | 0.110 |
Why?
|
Hospitals, General | 1 | 2017 | 749 | 0.110 |
Why?
|
Appointments and Schedules | 1 | 2016 | 414 | 0.110 |
Why?
|
Adult | 15 | 2022 | 213712 | 0.100 |
Why?
|
Interviews as Topic | 1 | 2019 | 2536 | 0.100 |
Why?
|
Sex Distribution | 1 | 2017 | 2295 | 0.100 |
Why?
|
United States | 6 | 2023 | 69693 | 0.100 |
Why?
|
Age Distribution | 1 | 2017 | 2900 | 0.100 |
Why?
|
Massachusetts | 2 | 2021 | 8662 | 0.100 |
Why?
|
South Africa | 5 | 2015 | 1728 | 0.100 |
Why?
|
Truth Disclosure | 1 | 2015 | 435 | 0.090 |
Why?
|
Social Class | 1 | 2019 | 1995 | 0.090 |
Why?
|
HIV Infections | 5 | 2015 | 16678 | 0.090 |
Why?
|
Bacteriological Techniques | 1 | 2010 | 276 | 0.090 |
Why?
|
Ambulatory Care Facilities | 1 | 2015 | 932 | 0.080 |
Why?
|
HIV Seropositivity | 1 | 2015 | 970 | 0.080 |
Why?
|
Rural Population | 2 | 2019 | 2207 | 0.080 |
Why?
|
Community Health Services | 1 | 2013 | 650 | 0.080 |
Why?
|
Male | 13 | 2021 | 349538 | 0.080 |
Why?
|
GTP-Binding Protein Regulators | 1 | 2007 | 13 | 0.080 |
Why?
|
Anti-Retroviral Agents | 2 | 2015 | 1712 | 0.080 |
Why?
|
GTP-Binding Protein beta Subunits | 1 | 2007 | 33 | 0.080 |
Why?
|
Opiate Substitution Treatment | 2 | 2023 | 404 | 0.080 |
Why?
|
Retinal Bipolar Cells | 1 | 2007 | 47 | 0.080 |
Why?
|
Mass Screening | 2 | 2015 | 5238 | 0.080 |
Why?
|
Young Adult | 5 | 2020 | 56350 | 0.070 |
Why?
|
Fellowships and Scholarships | 1 | 2014 | 1066 | 0.070 |
Why?
|
Receptors, Metabotropic Glutamate | 1 | 2007 | 212 | 0.070 |
Why?
|
Patient Compliance | 1 | 2016 | 2680 | 0.070 |
Why?
|
Health Personnel | 1 | 2019 | 3210 | 0.070 |
Why?
|
Middle Aged | 7 | 2020 | 213127 | 0.060 |
Why?
|
Female | 12 | 2020 | 379592 | 0.060 |
Why?
|
Healthcare Disparities | 1 | 2019 | 3151 | 0.060 |
Why?
|
Hospitalization | 2 | 2022 | 10232 | 0.060 |
Why?
|
Smoking | 1 | 2019 | 8969 | 0.050 |
Why?
|
Case-Control Studies | 1 | 2019 | 21719 | 0.050 |
Why?
|
Pandemics | 1 | 2020 | 8328 | 0.050 |
Why?
|
Cohort Studies | 2 | 2021 | 40450 | 0.050 |
Why?
|
Prevalence | 4 | 2022 | 15194 | 0.050 |
Why?
|
Primary Health Care | 1 | 2016 | 4551 | 0.040 |
Why?
|
Mycobacterium tuberculosis | 1 | 2010 | 1825 | 0.040 |
Why?
|
Aged | 4 | 2020 | 162944 | 0.040 |
Why?
|
Referral and Consultation | 2 | 2022 | 3527 | 0.040 |
Why?
|
Ontario | 1 | 2019 | 381 | 0.040 |
Why?
|
Tuberculosis | 1 | 2010 | 1904 | 0.040 |
Why?
|
Retrospective Studies | 3 | 2022 | 77098 | 0.040 |
Why?
|
Anti-HIV Agents | 2 | 2010 | 4250 | 0.040 |
Why?
|
Retina | 1 | 2007 | 2611 | 0.040 |
Why?
|
Adolescent | 3 | 2019 | 85649 | 0.030 |
Why?
|
Analgesics | 1 | 2022 | 1037 | 0.030 |
Why?
|
Outpatient Clinics, Hospital | 1 | 2016 | 392 | 0.030 |
Why?
|
Pharmaceutical Preparations | 1 | 2022 | 1071 | 0.030 |
Why?
|
Suicide, Attempted | 1 | 2022 | 1218 | 0.030 |
Why?
|
Suicidal Ideation | 1 | 2022 | 1246 | 0.030 |
Why?
|
Odds Ratio | 2 | 2019 | 9846 | 0.030 |
Why?
|
Treatment Outcome | 1 | 2018 | 62966 | 0.030 |
Why?
|
Urban Population | 1 | 2019 | 2018 | 0.020 |
Why?
|
Family Characteristics | 1 | 2015 | 999 | 0.020 |
Why?
|
Cost-Benefit Analysis | 1 | 2023 | 5385 | 0.020 |
Why?
|
Patient Care Team | 1 | 2021 | 2527 | 0.020 |
Why?
|
Vulnerable Populations | 1 | 2015 | 685 | 0.020 |
Why?
|
Sputum | 1 | 2010 | 474 | 0.020 |
Why?
|
Protein Kinase C-alpha | 1 | 2007 | 112 | 0.020 |
Why?
|
CD4 Lymphocyte Count | 1 | 2013 | 2557 | 0.020 |
Why?
|
Program Evaluation | 1 | 2015 | 2485 | 0.020 |
Why?
|
Staining and Labeling | 1 | 2010 | 1099 | 0.020 |
Why?
|
Academic Medical Centers | 1 | 2016 | 2749 | 0.020 |
Why?
|
DNA, Bacterial | 1 | 2010 | 1465 | 0.020 |
Why?
|
Microscopy | 1 | 2010 | 903 | 0.020 |
Why?
|
Immunoprecipitation | 1 | 2007 | 905 | 0.020 |
Why?
|
Prospective Studies | 3 | 2015 | 53187 | 0.020 |
Why?
|
Patient Education as Topic | 1 | 2013 | 2275 | 0.010 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2021 | 9185 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2019 | 13921 | 0.010 |
Why?
|
Antiretroviral Therapy, Highly Active | 1 | 2010 | 1872 | 0.010 |
Why?
|
Polymerase Chain Reaction | 1 | 2010 | 6171 | 0.010 |
Why?
|
Socioeconomic Factors | 1 | 2015 | 7770 | 0.010 |
Why?
|
Incidence | 1 | 2015 | 20928 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2010 | 14720 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2015 | 39004 | 0.010 |
Why?
|
Risk Factors | 1 | 2016 | 72145 | 0.010 |
Why?
|
Mice | 1 | 2007 | 81045 | 0.000 |
Why?
|
Animals | 1 | 2007 | 168561 | 0.000 |
Why?
|